Work

Ovarian Cancer Therapy Today and Tomorrow: Unmet Needs, Innovations, and Clinical Pathways

Year: 2026

Type: article

Abstract: Despite advances with surgery, platinum-based chemotherapy, anti-angiogenics, and poly(ADP-ribose) polymerase (PARP) inhibition, the treatment of ovarian cancer remains challenging due to late presentation, molecular heterogeneity, rapid emergence of resistance, and a complex and dynamic tumor microenvironment (TME). In this perspective, we will discuss major challenges in ovarian cancer therapy, focusing on how the ovarian cancer TME, including both solid tumor lesions and malignant ascites, impacts therapeutic efficacy. We also discuss emerging therapies, both at the pre-clinical stage and in clinical trials.

Source: Gynecologic Cancer

DOI: 10.3390/gynecolcancer1010002

Authors: Jad C. Tannous, Dilihumaer Maimaitiming, Oladapo O. Yeku, Lei Xu, Zohreh Amoozgar

Institutions: Harvard University, Massachusetts General Hospital

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W7224449790

FWCI:

Cites: 169

Cited by:

Related to: 10